Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: A European randomized, controlled clinical trial

Journal of Hypertension

Volumn 32, Issue 8, 2014, Pages 1700-1707

  Mancia, Giuseppe ^a   Coca, Antonio ^b   Chazova, Irina ^c   Girerd, Xavier ^d   Haller, Hermann ^e   Pauletto, Paolo ^f   Pupek Musialik, Danuta ^g   Svyshchenko, Yevgeniya ^h  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Department of Systemic Hypertension ^*  (Russian Federation)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF PADOVA   (Italy)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^h Ukranian Strazhesko Institute of Cardiology   (Ukraine)

Author keywords

combination therapy; enalapril; essential hypertension (Stage 2); factorial study design; home blood pressure; lercanidipine

Indexed keywords

ENALAPRIL; LERCANIDIPINE; PLACEBO; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG COMBINATION;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEMALE; HEADACHE; HEART PALPITATION; HOME MONITORING; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED;

EID: 84904036094     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000239     Document Type: Article

References (33)

1. Mancia G, Fagard R, Krzysztof N, Narkiewicz K, Redon J, Zanchetti A, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281-1357.
2. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2011; 123:2434-2506.
3. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122:290-300.
4. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051. (Pubitemid 38781107)
5. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007; 120:713-719. (Pubitemid 47176510)
6. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310. (Pubitemid 32804122)
7. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31:982-988.
8. National Institute for Health and Clinical Excellence. Hypertension. Clinical management of clinical hypertension in adults. NICE Clinical Guideline 127. August 2011. London, UK: National Clinical Guideline Centre, Royal College of Physicians.
9. Dahlöf B, Sever P, Poulter NR, Wedel H, Beevers D, Caulfield M, et al., for the ASCOT investigators et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet 2005; 366:895-906. (Pubitemid 41265663)
10. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
11. Lund-Johansen P, Stranden E, Helberg S, Wessel-Aas T, Risberg K, Ronnevik PK, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003; 21:1003-1010. (Pubitemid 36677166)
12. Schrier RW, Estacio RO, Jeffers B. Appropriate blood pressure control in NIDDM (ABCD) trial. Diabetologia 1996; 39:1646-1654. (Pubitemid 26397382)
13. Wing LM, Reid CM, Ryan P, et al. for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting- enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592. (Pubitemid 36204952)
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
15. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316:1429-1435.
16. Meredith PA. Lercanidipine: A novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Exp Opin Invest Drugs 1999; 8:1043-1062. (Pubitemid 29329037)
17. Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, Crepaldi G. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study. Diab Nutr Mtab 2004; 17:259-266. (Pubitemid 40124176)
18. Grassi G, Quarti-Trevano F, Scopelliti F, Seravalle G, Cuspidi C, Mancia G. Effect of long term lercanidipine or hydrochlorotiazide administration on hypertension-related vascular structural changes. Blood Pressure 2006; 15:268-274.
19. Grassi G, Seravalle G, Turri C, Bolla G, Mancia G. Short-versus longterm effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41:558-562. (Pubitemid 36314632)
20. Mancia G, Grassi G. The central sympathetic nervous system in hypertension. Handb Clin Neurol 2013; 117:329-335.
21. Hair PI, Scott LJ, Perry CM. Fixed dose-combination Lercanidipine/ Enalapril. Drugs 2007; 67:95-106.
22. Chatzikyrkou C, Haller H, Menne J. Efficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertension. Clin Med Ther 2009; 1:63-76.
23. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: A summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008; 26:1505-1530.
24. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, et al.Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95:1464-1470. (Pubitemid 27142804)
25. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population. Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111:1777-1783. (Pubitemid 40525142)
26. Stergiou GS, Jaenecke B, Giovas PP, Chang A, Chung-Yueh Y, Tan TM. A tool for reliable self-home blood pressure monitoring designed according to the European Society of Hypertension recommendations: The Microlife WatchBP Home monitor. Blood Press Monit 2007; 12:127-131. (Pubitemid 46412120)
27. Bombelli M, Facchetti R, Fodri D, Brambilla G, Sega R, Grassi G, Mancia G. Impact of body mass index and waist circumpherence on the cardiovascular risk and all-cause death in a general population: data from the PAMELA study. Nutr Metab Cardiovasc Dis 2013; 23:650-656.
28. Mancia G, Sega R, Grassi G, Cesana G, Zanchetti A. Defining ambulatory and home blood pressure normality: further considerations based on data from the PAMELA study. J Hypertens 2001; 19:995-999. (Pubitemid 32493630)
29. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al. European Society of Hypertension guidelines for blood pressure monitoring. J Hum Hypertens 2010; 24:779-785.
30. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28:1584-1590.
31. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610-618.
32. Sokol MD, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43:521-530. (Pubitemid 40847288)
33. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15.